Auto-generated from public data. Not the firm's stated position.
Birk Venture appears to focus on early-stage biotech and healthtech companies, with particular emphasis on oncology and immunotherapy based on disclosed portfolio companies. Recent investment activity suggests a concentration in pre-seed and seed stage funding with check sizes ranging from €0.1M to €1.5M, primarily targeting companies developing novel therapeutic modalities.
Generated 14 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.